Pulsed field ablation of the posterior nasal nerve for chronic rhinitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multi-center, single-arm, non-significant-risk study of the NOVOCLEAR™ Device used with the AVENTIX™ PFX System to treat chronic rhinitis. The device delivers non-thermal pulsed field energy to soft tissues in the nasal airway, including the posterior nasal nerve distribution. Adults 18–85 with symptoms for more than six months and rTNSS ≥6 who have insufficient response to nasal steroids will be enrolled and treated at participating ENT centers. Safety, tolerability, and symptom changes will be followed over scheduled visits after the procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subject is 18 to 85 years of age.
2. The subject has had symptoms of chronic rhinitis for greater than 6 months with insufficient response to nasal steroids.
3. The subject has an rTNSS total score of ≥ 6.
4. The subject has had moderate to severe symptoms of rhinorrhea and/or nasal congestion (rTNSS rating of 2 or 3 for rhinorrhea and 1, 2, or 3 for congestion)
5. The subject is able and willing to provide written informed consent and comply with the protocol requirements.

Exclusion Criteria:

1. The subject has clinically significant anatomic obstructions on either side that limit access to the posterior nose, including severe septal deviation, nasal polyps, and sinonasal tumor
2. The subject has a septal perforation
3. The subject has had prior sinus or nasal surgery on either side that significantly alters the anatomy of the posterior nose.
4. The subject had had previous surgery of the PNN for chronic rhinitis.
5. The subject has had prior head or neck irradiation
6. The subject has an active or chronic nasal or sinus infection
7. The subject has active coagulation disorder, or the patient is receiving anticoagulants
8. The subject has a history of dry eye or dry nose symptoms
9. Patient has rhinitis medicamentosa
10. The subject has ocular allergic symptoms
11. The subject has a history of nose bleeds
12. The subject has electrically sensitive implants (e.g. cochlear implants, pacemakers, defibrillators)
13. The subject is pregnant or lactating
14. The subject is participating in another clinical research study
15. The subject has an allergy or intolerance to anesthetic agent
16. Any physical condition that, in the Investigator's opinion, would prevent adequate study participation or pose an increased risk

Where it's running

• Colorado ENT and Allergy
  Colorado Springs, Colorado, United States Recruiting
• Bay Area ENT
  Ocean Springs, Mississippi, United States Recruiting
• Atkins Expert Sinus Care
  San Antonio, Texas, United States Recruiting

Study contacts

• Principal investigator: Raymond Weiss, MD — Bay Area ENT
• Study coordinator: ClinicalAdmin
• Email: clinical@aventixmed.com
• Phone: (510) 912-2589

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cryotherapy to the back of the nose to ease runny nose symptoms

  This study tests whether a cold, in-clinic treatment can help adults with chronic rhinitis who continue to have watery noses despite standard care.

  Recruiting East and North Hertfordshire NHS Trust · Stevenage · NCT07917091

• Optimizing diagnosis of chronic rhinitis with a nasal allergen provocation test

  This project will test whether a nasal allergen provocation test helps diagnose adults with chronic rhinitis by comparing patients with suspected allergic rhinitis to healthy volunteers.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06999044

• Understanding chronic rhinitis in China

  This study is trying to learn more about chronic rhinitis by gathering information from 30,000 people in China to help improve treatments and prevention strategies.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06370468

• Mannan-Conjugated Allergoids for House Dust M mite Allergy

  A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.

  Recruiting at 2 sites Phase 3 Inmunotek S.L. · Covilha, Castelo Branco District and 15 other locations · NCT07904195

• Mannan-conjugated Allergoids for House Dust Mite Allergy

  A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.

  Recruiting at 4 sites Phase 3 Inmunotek S.L. · Coimbra and 15 other locations · NCT07904052

• Dog-allergy immunotherapy with Alutard SQ Dog in Swedish practice

  This study tests whether Alutard SQ Dog immunotherapy helps adults with moderate-to-severe dog allergy when used in real-world Swedish care.

  Recruiting at 2 sites Phase 4 Karolinska Institutet · Lund, Skåne County and 1 other locations · NCT07651891

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.